PROFESSOR PATENT: mRNA & LNP WAR ROOM
Neuro-symbolic wargaming across the 5-layer mRNA and LNP patent thicket (UPenn, BioNTech, CureVac, Arbutus, Moderna). Automating 35 U.S.C. § 103 Allergan/DuPont LNP molar overlap (91.5%), § 112(a) Amgen v. Sanofi codon genus overbreadth (10.38 > 3.0), and MCTS tumor-selective logic circuits with quadruple-vitiated LNP delivery.
UPenn US 8,278,036 Expires August 21, 2026: Base Nucleoside Chemistry Becomes Public Domain
The foundational patent monopolizing pseudouridine ($\Psi$) and N1-methylpseudouridine ($m1\Psi$) incorporation for TLR7/TLR8 evasion reaches its statutory 20-year term cliff in August 2026. After this inflection, all commercial freedom-to-operate battles shift exclusively to Layers 2–5 (5'/3' UTRs, split poly(A) tails, and 4-component LNP formulation windows).
Statutory base expiration on August 21, 2026 completely frees pseudouridine and N1-methylpseudouridine nucleoside chemistry to the global public domain.
Claims strictly require linear 5' Cap, AES-mtRNR1 tandem 3' UTR, and interrupted A30-L10-A70 poly(A) tail. Circular RNA (circRNA) and histone-stem-loop/triple-helix locks achieve complete All-Elements Rule vitiation under Warner-Jenkinson.
Fatal lack of full-scope enablement under 35 U.S.C. § 112(a) and Amgen v. Sanofi (143 S. Ct. 1243). Claims an astronomical genus exceeding 10^12 variants based on only 42 specification examples (Amgen Score: 10.38 > 3.0).
Prima facie obvious under 35 U.S.C. § 103 (Allergan / DuPont) over prior art WO 2005/120469 (91.5% obviousness probability). Furthermore, fully vitiated by substituting beta-sitosterol and polysarcosine (0.0% cholesterol, 0.0% PEG).
Narrow species patent strictly tied to SM-102 branched amino-ester; bypassed by biodegradable disulfide ionizable lipids or multivalent dendrimers.
35 U.S.C. § 271(e)(1) BPCIA Safe-Harbor Pre-Launch Physics
Under the statutory experimental-use exemption of 35 U.S.C. § 271(e)(1) (*Merck KGaA v. Integra Lifesciences*), pre-clinical synthesis, formulation optimization, and Phase 1 trial generation of non-infringing mRNA circuits is completely insulated against patent infringement actions. This enables sponsors to complete full IND-enabling toxicology and clinical batches prior to August 2026, launching commercial delivery instantly as the UPenn patent clears.